CDI Laboratories HuProt v4. 0 Human Proteome Microarrays with Biospecimen Screening Service and Analysis
The National Institute on Drug Abuse (NIDA), a component of the Department of Health and Human Services National Institutes of Health, has awarded contract 75N95025P00168 to CDI Laboratories Inc. for HuProt v4.0 Human Proteome Microarrays with Biospecimen Screening Service and Analysis. The contract, valued at $50,000, was awarded on March 17, 2025, without utilizing a specific set-aside designation. The award was not the result of a competitive solicitation process, and the contract appears to involve specialized scientific research services related to human proteome microarray technology and associated screening and analytical capabilities.
75N95025P00168 Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse
3/17/25, 1:53 PM CDI Laboratories HuProt v4. 0 Human Proteome Microarrays (100) with Biospecimen Screening Service and Analysis
The National Institute on Drug Abuse (NIDA), acting on behalf of the National Institute of Mental Health (NIMH), is seeking to procure 100 HuProt v4.0 Human Proteome Microarrays with Biospecimen Screening Service and Analysis through a non-competitive solicitation. The Translational Immunopsychiatry Unit (TIU) intends to use these microarrays for autoantibody discovery and validation, specifically screening for autoantibodies that bind to conformational and post-translationally modified human proteins. The solicitation is structured as a combined synopsis/solicitation for commercial products and services under simplified acquisition procedures, with a firm fixed-price purchase order anticipated. Evaluation criteria will prioritize technical capability and past performance, which are considered significantly more important than price. Potential offerors must submit their electronic responses by Tuesday, March 11, 2025, at 9:00 am Eastern Time, including details such as unit pricing, shipping costs, delivery terms, and unique entity identification.
The solicitation is designated as a total small business set-aside, with a NAICS code of 541380 and a small business size standard of $19 million. The specific contract is intended to be awarded directly to CDI Laboratories Inc., located in Mayaguez, Puerto Rico, without full and open competition. The anticipated purchase order will have a performance period from March 17, 2025, to June 17, 2025, and is not expected to exceed the simplified acquisition threshold. The microarrays must contain over 21,000 human proteins derived from 16,794 unique human genes, with high reproducibility requirements of R^2 > 95%. Responses must be submitted electronically to Contracting Officer Marlene Milgram, with offerors required to maintain an active System for Award Management (SAM) registration and provide comprehensive documentation demonstrating their capability to fulfill the stated requirements.
75N95025Q00167 Department of Health and Human Services National Institutes of Health National Institute on Drug Abuse
3/7/25, 8:34 PM